Article

Please Donate Blood!

Author(s):

Onclive Team

Amid the COVID-19 pandemic and in an effort to help our community, OncLive's parent company will be hosting the virtual MJH Life Sciences Sleeves Up Blood Drive from March 31 through April 30.

During times like these, we must come together and help those in need. Amid the COVID-19 pandemic and in an effort to help our community, OncLive’s parent company will be hosting the virtual MJH Life Sciences Sleeves Up Blood Drive from March 31 through April 30. Every pint of blood donated can save up to 3 lives.

Companies or groups interested in hosting virtual drives can go to https://sleevesup.redcrossblood.org/. Those who would like to donate can download the American Red Cross Blood Donor app.

Then please spread the word on social media that people can help the American Red Cross continue to deliver its lifesaving mission nationwide because of this public health emergency by texting REDCROSS to #90999 to make a $10 donation, visiting redcross.org, or calling 1-800-REDCROSS to donate.

Thank you!

#MJHSleevesUp #PharmacyTimesSleevesUp

Related Videos
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation To Address The Evolved Landscape Of EGFR Mutant NSCLC
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Daniel M. Halperin, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
BTK Inhibitors in CLL : Second Generation Drugs and Beyond
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Related Content
Georgina V. Long, MD, MSc, of The University of Sydney
June 1st 2024

Up to 10 Years of Follow-Up Uphold Survival Benefit With Adjuvant Dabrafenib/Trametinib in Stage III Melanoma

Benjamin Levy, MD, clinical director, medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospital; associate professor, oncology, Johns Hopkins University School of Medicine
May 30th 2024

Levy Lends Insights Into the Current and Future Use of ADCs in NSCLC

George Yaghmour, MD
May 31st 2024

Half-Matched Family Donors Offer Best Outcomes for Hispanic Patients Undergoing Bone Marrow Transplants

Oncology Unplugged
May 30th 2024

Park and Sonpavde on Considerations for Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

FDA
May 31st 2024

FDA Accepts BLA Resubmission for Zolbetuximab in CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma

Jorge E. Cortes, MD, of Georgia Cancer Center at Augusta University
May 31st 2024

Asciminib Bests Standard-of-Care TKIs in Ph+ CML